☆ 4.5 Letter

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

BLOOD CANCER JOURNAL (2015)

期刊

BLOOD CANCER JOURNAL

卷 5, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/bcj.2015.80

关键词

-

类别

Oncology Hematology

资金

NCI NIH HHS [P30 CA016672] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Targeting Leukemia-Initiating Cells in Acute Lymphoblastic Leukemia

Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra

Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.

CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression

Shinsuke Suzuki, Sawako Hourai, Kimiharu Uozumi, Yuichirou Uchida, Makoto Yoshimitsu, Hachiman Miho, Naomichi Arima, Shin-Ichi Ueno, Kenji Ishitsuka

Summary: This study reveals that NOTCH1 protein is constitutively activated but likely a passenger in NOTCH1-mutation-negative ATL cell proliferation. Furthermore, GSI does not suppress the growth of ATL cell lines.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Amber Gibson, Adriana Trabal, David McCall, Sajad Khazal, Laurie Toepfer, Donna H. Bell, Michael Roth, Kris M. Mahadeo, Cesar Nunez, Nicholas J. Short, Courtney DiNardo, Marina Konopleva, Ghayas C. Issa, Farhad Ravandi, Nitin Jain, Gautam Borthakur, Hagop M. Kantarjian, Elias Jabbour, Branko Cuglievan

Summary: This study retrospectively reviewed the safety and efficacy of Venetoclax in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma (LBL). The results showed that Venetoclax is safe and effective to use in pediatric patients with ALL/LBL and should be considered in both the relapsed and upfront settings.

CANCERS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia

Bhupendra Kaushik, Dilipkumar Pal

Summary: T-cell acute lymphoblastic leukemia (T-ALL) is mainly treated with chemotherapy, but recent studies on the NOTCH signaling pathway suggest potential new targeted therapies. While gamma-secretase inhibitors have shown promising results in targeting NOTCH signaling in T-ALL cell lines, mutations in NOTCH1 do not always predict sensitivity to these inhibitors. Therefore, a combination regimen may be necessary for effective long-term treatment against T-ALL.

CURRENT DRUG TARGETS (2021)

添加到收藏夹

Article Oncology

Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia

Giulia Veltri, Federica Lovisa, Giuliana Cortese, Marta Pillon, Elisa Carraro, Simone Cesaro, Massimo Provenzi, Salvatore Buffardi, Samuela Francescato, Alessandra Biffi, Barbara Buldini, Valentino Conter, Valentina Serafin, Lara Mussolin

Summary: T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) share common features but have different phosphoproteomic profiles. A proteomic signature of six proteins can distinguish stage IV T-LBL from T-ALL, and AKT hyperphosphorylation alone can distinguish stage IV T-LBL from both T-ALL and stage III T-LBL.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target

Hugo Larose, Nina Prokoph, Jamie D. Matthews, Michaela Schlederer, Sandra Hoegler, Ali F. Alsulami, Stephen P. Ducray, Edem Nuglozeh, Mohammad Feroze Fazaludeen, Ahmed Elmouna, Monica Ceccon, Luca Mologni, Carlo Gambacorti-Passerini, Gerald Hoefler, Cosimo Lobello, Sarka Pospisilova, Andrea Janikova, Wilhelm Woessmann, Christine Damm-Welk, Martin Zimmermann, Alina Fedorova, Andrea Malone, Owen Smith, Mariusz Wasik, Giorgio Inghirami, Laurence Lamant, Tom L. Blundell, Wolfram Klapper, Olaf Merkel, G. A. Amos Burke, Shahid Mian, Ibraheem Ashankyty, Lukas Kenner, Suzanne D. Turner

Summary: This study identified a variant in the extracellular domain of NOTCH1 in ALCL patients, demonstrating that the Notch pathway is a viable second-line druggable target for ALK(+) ALCL.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Oncology

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia

Inge Govaerts, Cristina Prieto, Charlien Vandersmissen, Olga Gielen, Kris Jacobs, Sarah Provost, David Nittner, Johan Maertens, Nancy Boeckx, Kim De Keersmaecker, Heidi Segers, Jan Cools

Summary: In the treatment of T-ALL, combination treatment strategies using PSEN1-selective gamma-secretase inhibitor MRK-560 with other targeted agents show synergistic effects, reducing leukemia infiltration and providing survival benefits.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Mengping Xi, Shanshan Guo, Caicike Bayin, Lijun Peng, Florent Chuffart, Ekaterina Bourova-Flin, Sophie Rousseaux, Saadi Khochbin, Jian-Qing Mi, Jin Wang

Summary: This study found that the HDAC inhibitor chidamide has an anti-tumor effect on T-ALL cells, particularly by inhibiting the NOTCH1-MYC signaling axis. Clinical trial results support that chidamide treatment reduces minimal residual disease in patients and is well tolerated.

FRONTIERS OF MEDICINE (2022)

添加到收藏夹

Review Hematology

Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma

Yuan-hong Huang, Chao-Ling Wan, Hai-ping Dai, Sheng-li Xue

Summary: T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite improvements in survival, relapsed and refractory T-ALL remains a significant challenge. Next-generation sequencing has identified new therapeutic targets and immunotherapies, such as NOTCH1 inhibitors and CAR T cell therapy, for T-ALL/LBL. This review discusses the progress and future directions of these targeted therapies and immunotherapies.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma

Gautam Borthakur, Giovanni Martinelli, Emmanuel Raffoux, Patrice Chevallier, Jorg Chromik, Andrew Lithio, Claire L. Smith, Eunice Yuen, Gerard Joseph Oakley, Karim A. Benhadji, Daniel J. DeAngelo

Summary: The study included 36 patients with T-ALL (n = 31, 86.1%) or T-LBL (n = 5, 13.9%) who received treatment with Crenigacestat and dexamethasone, with the maximum tolerated dose being 75 mg of Crenigacestat plus 24 mg of dexamethasone daily. Overall, Crenigacestat demonstrated limited clinical activity in adult patients with relapsed/refractory T-ALL/T-LBL.

CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia

Robert Chiesa, Christos Georgiadis, Farhatullah Syed, Hong Zhan, Annie Etuk, Soragia Athina Gkazi, Roland Preece, Giorgio Ottaviano, Toni Braybrook, Jan Chu, Agnieszka Kubat, Stuart Adams, Rebecca Thomas, Kimberly Gilmour, David O'Connor, Ajay Vora, Waseem Qasim

Summary: Base editing technique has been used to inactivate genes and treat relapsed childhood T-cell leukemia with promising results.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Pathology

sTRBC1 and cyTRBC1 Expression Distinguishes Indolent T-Lymphoblastic Proliferations From T-Lymphoblastic Leukemia/Lymphoma

Juan Liu, Mingyong Li, Jun Fu, Min Dong, Xiaoming Fan, Ling Zhong, Gang Xu, Yanxin Li, Qian Xi

Summary: Indolent T-lymphoblastic proliferation (iT-LBP) is a non-neoplastic T-cell proliferation in extrathymic tissues that requires no treatment. Distinguishing iT-LBP from T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) can be challenging due to overlapping features. Evaluation of TRBC1 expression patterns can serve as a simple and effective approach to differentiate between iT-LBP and T-ALL/LBL.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2023)

添加到收藏夹

Article Hematology

Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia

Yizhen Li, Xu Yang, Yu Sun, Zhenhua Li, Wenjian Yang, Bensheng Ju, John Easton, Deqing Pei, Cheng Cheng, Shawn Lee, Ching-Hon Pui, Jiyang Yu, Hongbo Chi, Jun J. Yang

Summary: T-cell immunity plays a pivotal role in maintaining long-term remission of acute lymphoblastic leukemia (ALL) and the interplay between host immunity and drug resistance can be harnessed to improve chemotherapy outcomes for ALL.

BLOOD (2022)

添加到收藏夹

Article Oncology

The circadian clock circuitry modulates leukemia initiating cell activity in T-cell acute lymphoblastic leukemia

Emanuele Murgo, Elisabetta De Santis, Francesca Sansico, Valentina Melocchi, Tommaso Colangelo, Costanzo Padovano, Mattia Colucci, Annalucia Carbone, Beatrice Totti, Alireza Basti, Lisa Gottschlich, Angela Relogio, Nazzareno Capitanio, Fabrizio Bianchi, Gianluigi Mazzoccoli, Vincenzo Giambra

Summary: This study investigates the role of the biological clock in the regulation of cellular dynamics in T-ALL. The disruption of the circadian clock negatively affects LIC activity and JAK/STAT signaling in T-ALL cells. Targeting circadian components could be a potential therapeutic strategy for T-ALL treatment.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Oncology

Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?

Ziting Zhang, Kun Yang, Han Zhang

Summary: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and heterogeneous subtype of cancer. Recent studies have shown the important roles of leukemia-initiating cells (LICs) and leukemic niches in the initiation and progression of T-ALL, leading to the development of targeted therapies.

CANCERS (2022)

添加到收藏夹

Article Oncology

Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment

Chiara Sartor, Mario Arpinati, Gabriella Chirumbolo, Luca Dozza, Gianluca Cristiano, Jacopo Nanni, Giovanni Marconi, Valentina Robustelli, Ilaria Vigliotta, Sarah Parisi, Carolina Terragna, Nicoletta Testoni, Stefania Paolini, Giovanni Martinelli, Antonio Curti, Michele Cavo, Cristina Papayannidis

Summary: Antigen-directed target therapy is now the standard of care for B-cell acute lymphoblastic leukemia. The expression percentage and fluorescent intensity of CD22 on leukemic blast cells have an impact on patient outcomes. Higher CD22-FI is associated with better response rates and overall survival.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments

Beatrice Aramini, Valentina Masciale, Chiara Arienti, Massimo Dominici, Franco Stella, Giovanni Martinelli, Francesco Fabbri

Summary: The roles and connections of small molecules such as cancer stem cells, circulating tumor cells, and cancer-associated fibroblasts in solid tumors have been under-debated but of significant interest in recent decades. These molecules may play a role in tumor recurrence, drug resistance, and treatment response, but their mechanisms and molecular pathways are still unknown. Defining new molecules to fight against cancer is of great interest to the scientific community. Cancer stem cells, circulating tumor cells, and cancer-associated fibroblasts play important roles in the tumor microenvironment, and discovering biomarkers related to these cell populations and defining the network among them and the tumor microenvironment are becoming increasingly important.

CANCERS (2022)

添加到收藏夹

Article Oncology

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

Paola Ulivi, Milena Urbini, Elisabetta Petracci, Matteo Canale, Alessandra Dubini, Daniela Bartolini, Daniele Calistri, Paola Cravero, Eugenio Fonzi, Giovanni Martinelli, Ilaria Priano, Kalliopi Andrikou, Giuseppe Bronte, Lucio Crino, Angelo Delmonte

Summary: Molecular characterization of advanced non-small-cell lung cancer (NSCLC) is essential for treatment decision making, and next-generation sequencing (NGS) is the best strategy in this context. In this study, we analyzed a series of young NSCLC patients using a wide NGS gene panel assay. The most frequently mutated genes were TP53, KRAS, STK11, etc. We found a significant association between STK11 and KRAS mutations and high tumor mutational burden (TMB), while EGFR and EML4-ALK alterations were more common in tumors with low TMB. The results obtained from this approach showed perfect concordance with those obtained from a single or few genes approach.

CANCERS (2022)

添加到收藏夹

Article Oncology

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia

Simona Soverini, Sara De Santis, Margherita Martelli, Cecilia Monaldi, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Manuela Mancini, Samantha Bruno, Claudia Venturi, Katerina Machova Polakova, Thomas Ernst, Dianna Maar, Adam Corner, Michele Cavo

Summary: This study evaluated a multiplex strategy based on ddPCR for the detection and quantitation of mutations conferring resistance to second-generation TKIs. The results showed that ddPCR can accurately and rapidly screen for 2GTKI-resistant mutations.

LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Monica Messina, Alfonso Piciocchi, Tiziana Ottone, Stefania Paolini, Cristina Papayannidis, Federica Lessi, Nicola Stefano Fracchiolla, Fabio Forghieri, Anna Candoni, Andrea Mengarelli, Maria Paola Martelli, Adriano Venditti, Angelo Michele Carella, Francesco Albano, Valentina Mancini, Bernardi Massimo, Valentina Arena, Valeria Sargentini, Mariarita Sciume, Domenico Pastore, Elisabetta Todisco, Giovanni Roti, Sergio Siragusa, Marco Ladetto, Stefano Pravato, Eleonora De Bellis, Giorgia Simonetti, Giovanni Marconi, Claudio Cerchione, Paola Fazi, Marco Vignetti, Sergio Amadori, Giovanni Martinelli, Maria Teresa Voso

Summary: IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol confirms that IDH1/2 mutations are frequently detected at diagnosis and emphasizes the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors. In the subset of IDH1/2-mutated patients, complete remission achievement rate and overall survival at 2 years were similar to IDH1/2-WT patients.

CANCERS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon

Andrea Ghelli Luserna di Rora, Mouna Jandoubi, Giovanni Martinelli, Giorgia Simonetti

Summary: Uncontrolled proliferative signals and cell cycle dysregulation are important drivers of leukemia, and new compounds targeting cell cycle proteins and oncogenic mechanisms show promising therapeutic potential. The development of kinase inhibitors, microtubule-depolymerizing agents, P53-restoring agents, G-quadruplex-stabilizing molecules, and inhibitors of CDK2, CHK1, PI3K delta, STAT5, BRD4, and BRPF1 have shown effectiveness in inhibiting leukemia growth. Further investigation is needed to evaluate their toxicity, bio-availability, and efficacy in clinical settings.

MOLECULES (2023)

添加到收藏夹

Article Nutrition & Dietetics

The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling

Sara Salucci, Alberto Bavelloni, Anna Bartoletti Stella, Francesco Fabbri, Ivan Vannini, Manuela Piazzi, Karyna Volkava, Katia Scotlandi, Giovanni Martinelli, Irene Faenza, William Blalock

Summary: Approximately 7% of childhood cancers and 1% of adult cancers are soft tissue sarcomas, with rhabdomyosarcoma being the most common subtype. Despite current therapeutic protocols, survival rates for RMS have not improved significantly in the past decade. Curcumin, derived from the Curcuma longa plant, has low toxicity and has shown anti-tumorigenic effects in vitro. This study evaluated curcumin's activity in RMS cell lines and identified the major pathways affected by curcumin's anti-tumorigenic effects. Curcumin treatment resulted in cell cycle arrest, inhibited migration and colony formation, and induced apoptosis. Proteome profiler analysis revealed that curcumin primarily influenced signaling through AKT-mTOR, STAT, AMPK, and p53 pathways in a subtype-specific manner. Combinational therapeutic targeting of these pathways may be the best option for RMS treatment.

NUTRIENTS (2023)

添加到收藏夹

Article Genetics & Heredity

Detection of a Novel MSI2-C17orf64 Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report

Anna Ferrari, Roberto Fiocca, Elena Bonora, Chiara Domizio, Eugenio Fonzi, Davide Angeli, Gian Domenico Raulli, Sandro Mattioli, Giovanni Martinelli, Chiara Molinari

Summary: This study conducted genomic analysis on a neoadjuvant chemotherapy-resistant gastroesophageal tumor and identified a novel gene fusion, MSI2-C17orf64, that has never been reported before. This finding highlights the potential of MSI2 as a therapeutic target.

GENES (2023)

添加到收藏夹

Article Oncology

Correlations between Molecular Alterations, Histopathological Characteristics, and Poor Prognosis in Esophageal Adenocarcinoma

Arianna Orsini, Luca Mastracci, Isotta Bozzarelli, Anna Ferrari, Federica Isidori, Roberto Fiocca, Marialuisa Lugaresi, Antonietta D'Errico, Deborah Malvi, Erica Cataldi-Stagetti, Paola Spaggiari, Anna Tomezzoli, Luca Albarello, Ari Ristimaki, Luca Bottiglieri, Kausilia K. Krishnadath, Riccardo Rosati, Uberto Fumagalli Romario, Giovanni De Manzoni, Jari Rasanen, Giovanni Martinelli, Sandro Mattioli, Elena Bonora

Summary: Esophageal adenocarcinoma (EAC) is a severe malignancy with increasing incidence, poorly understood pathogenesis, and low survival rates. TP53 gene alterations, especially missense mutations, negatively affect cancer-specific survival in EAC. HNF1alpha gene disruption is associated with other gene alterations and is identified as a new EAC-mutated gene.

CANCERS (2023)

添加到收藏夹

Review Oncology

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi

Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.

CANCERS (2023)

添加到收藏夹

Review Hematology

How I Manage Chronic Lymphocytic Leukemia

Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli, Alessandra Ferrajoli

Summary: Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. Targeted therapies, including BTK inhibitors and BCL2 inhibitors, have become the standard of care for CLL treatment in the United States and Europe. These therapies have a good safety profile overall, but can also have unique toxicities.

HEMATOLOGY REPORTS (2023)

添加到收藏夹

Meeting Abstract Oncology

An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.

Raajit Rampal, Sundra Ramanathan, Cristina Papayannidis, Nikolas Von Bubnoff, Maria Del Mar Tormo Diaz, Maria Belen Vidriales, Adolfo De la Fuente Burguera, Lucia Masarova, Haifa Kathrin Al-Ali, David Lavie, Sandrine Niyongere, Tiffanie Chan, Jesse S. McGreivy, Wayne P. Rothbaum, Alice S. Mims, Thomas Cluzeau

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Courtney Denton Dinardo, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Amer Methqal Zeidan, Clara Chen, Jennifer Lord-Bessen, Peiwen Yu, Ling Shi, Shien Guo, Iryna Bluemmert, Xin Yu, Maroof Hasan, Patricia Martin Regueira, Stephane De Botton

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Hematology

INTERFERON-GAMMA-DEPENDENT IDO1 UP-REGULATION IN THE BONE MARROW MICROENVIRONMENT IS ASSOCIATED WITH INCREASED T REGULATORY CELLS AND WORSE CLINICAL OUTCOMES IN ACUTE MYELOID LEUKEMIA PATIENTS

G. Corradi, B. Bassani, G. Simonetti, S. Sangaletti, J. Vadakekolathu, M. Pazzaglia, C. Tripodo, G. Cristiano, L. Bandini, E. Ottaviani, M. Piccioli, G. Martinelli, M. P. Colombo, S. Rutella, M. Cavo, M. Ciciarello, A. Curti

HAEMATOLOGICA (2022)

添加到收藏夹

Meeting Abstract Hematology

FUSION LANDSCAPE IN ACUTE LEUKEMIAS: A SUBMERGED WORLD OF NOT ROUTINELY CHARACTERIZED TRANSCRIPTS

A. Ferrari, S. Vitali, E. Fonzi, C. Domizio, A. Ghelli Luserna Di Rora, M. Tebaldi, C. Papayannidis, A. Padella, M. T. Bochicchio, G. Marconi, D. Cangini, M. B. Giannini, M. Rondoni, A. M. Mianulli, B. Giannini, F. Giglio, C. Pasciolla, M. Fumagalli, A. Imovilli, M. Endri, S. Galimberti, G. Simonetti, G. Castellani, D. Remondini, D. Calistri, G. Martinelli

HAEMATOLOGICA (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.